This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. LB Pharmaceuticals raised $285 million in an initial ...

There are no signs so far that the new LB.1 variant is causing more severe disease in COVID-19 patients, the Centers for Disease Control and Prevention says, as infections have begun to accelerate in ...

LB Pharmaceuticals aims to show that what is old can become new again with a lead drug candidate that’s a modified version of a decades-old schizophrenia medication from Sanofi. The strategy is ...

As COVID-19 cases continue to rise across the United States, scientists are monitoring the spread of a new variant called LB.1. The highly contagious omicron subvariant, along with the fast-growing ...

Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...

LB Pharmaceuticals’ decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing this morning. The CNS-focused biotech ...

Despite the stagnant biotech IPO market of the last six months, LB Pharmaceuticals has set out plans to reel in hundreds of millions of dollars through its upcoming public debut. The ...

A summertime wave of COVID-19 infections is arriving earlier than last year across a growing share of the country, federal data suggests, as a new variant called LB.1 could be on track to become the ...